Aortic distensibility (AD) baseline and 2 years
| Comparison | AD (10−3 mm Hg−1) Geometric mean (95% CI) (unadjusted) | Ratio (95% CI), P value | ||||
| Unadjusted | Adjusted 1 | Adjusted 2 | ||||
| Combined TA1 and TA2 (n=81) Baseline 2 years | 3.0 (2.7 to 3.4) 3.6 (3.1 to 4.1) | 1.1 (1 to 1.4), 0.05 | na | na | ||
| TA1 at 2 years (all n=40) | TA2 at 2 years (all n=41) | 3.7 | 3.4 | 0.9 (0.7 to 1.2), 0.59 | 0.9 (0.7 to 1.2), 0.6 | 0.9 (0.7 to 1.2), 0.65 |
| Combined TA1 and TA2 at 2 years (non-responders n=38) | Combined TA1 and TA2 at 2 years (responders n=43) | 3.5 | 3.6 | 1.0 (0.8 to 1.4), 0.83 | 1.0 (0.8 to 1.4), 0.91 | 1.0 (0.7 to 1.4), 0.95 |
| TA1 at 2 years (non-responders n=17) | TA1 at 2 years (responders n=23) | 3.5 | 3.8 | 1.1 (0.7 to 1.7), 0.75 | 1.1 (0.6 to 1.7), 0.83 | 1.1 (0.6 to 1.8), 0.83 |
| TA1 at 2 years (responders n=23) | TA2a at 2 years (responders n=13) | 3.8 | 3.4 | 0.9 (0.6 to 1.4), 0.56 | 0.9 (0.6 to 1.5), 0.70 | 0.9 (0.5 to 1.6), 0.70 |
Differences between groups, either unadjusted, adjusted for baseline AD or (additionally) adjusted for age, sex, systolic blood pressure and pack years smoking (±baseline DAS28ESR as applicable).
Response assumed for patients whose responder status at 48 weeks was unknown.
AD, aortic distensibility (10-3mm Hg-1); Adjusted 1, adjusted for baseline AD; DAS28-ESR, Disease Activity Score-28 erythrocyte sedimentation rate; non-responders, patients with DAS28 >/=2.6 at 48 weeks; responders, patients with DAS28 <2.6 at 48 weeks; TA1, immediate etanercept (ETN) and methotrexate (MTX) treatment; TA2, first-line MTX ± additional conventional synthetic disease-modifying antirheumatic drug (csDMARD); TA2a, TA2 patients that continued csDMARD and did not escalate to delayed ETN/MTX at week 24.